clinical trial · NCT06717347
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
Merck Sharp & Dohme LLC·phase3·recruiting·n = 1,046
Diffuse Large B-Cell LymphomaZilovertamab vedotinRituximabCyclophosphamideDoxorubicinRituximab BiosimilarPrednisonePrednisoloneVincristine
brief summary
The purpose of this study is to evaluate if zilovertamab vedotin with standard treatment can help people live longer without the cancer growing or spreading than people who receive standard treatment alone.
started
Jan 27, 2025
primary completion
Jul 2, 2029
completion
Mar 29, 2032
last updated
May 15, 2026
official title
A Randomized, Open-Label, Multicenter, Phase 3 Study of Zilovertamab Vedotin (MK-2140) in Combination With R-CHP Versus R-CHOP in Participants With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) (waveLINE-010)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol